Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Eli Lilly Launches Zepbound KwikPen Multi-Dose Tirzepatide Pen for Adults With Obesity
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Eli Lilly’s Zepbound Gets FDA OK for Multi-Dose Pen
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Eli Lilly launches new form of obesity drug Zepbound with a month’s worth of doses in one pen
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Novo’s CagriSema Falls to Lilly’s Zepbound in Daring Head-to-Head Test
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
Multi-Dose KwikPen Now Available for Zepbound Administration - MPR
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
The next wave of GLP-1 drugs are coming—and they’re stronger than Wegovy and Zepbound
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.